Alpdogan Kantarci, DDS, MSc, PhD Applied Oral Sciences
The Forsyth Institute: Scientists & Research - Alpdogan Kantarci, DDS, MSc, PhD
Associate Member of the Staff
Department of Applied Oral Health Sciences
Pubmed Search - Alpdogan Kantarci
(Alpdogan Kantarci, DDS, MSc, PhD)
A Diplomate of the American Board of Periodontology and the current President of the Periodontal Research Group of the International Association for Dental Research, Dr. Kantarci focuses on improving periodontal and systemic health through the integration of clinical and laboratory research.
main interest is the characterization of inflammatory pathways of periodontal disease and utilization of this knowledge for development of novel therapeutic strategies to restore the homeostasis of periodontium.
Inflammation and resolution of inflammatory pathways in periodontal disease and diabetes
Research in the Kantarci lab focuses on investigation of the molecular mechanisms and resolution pathways of oral inflammation in patients with periodontitis, diabetes, and HIV infection.
Inflammation research is the center of Dr. Kantarci's
studies and he
has extensive experience in using experimental animal models for these diseases.
Specifically, Dr. Kantarci
focuses on the signal transduction mediated by lipids and various proteins in neutrophils and monocytes and their interaction with other cells of the oral cavity.
has developed several in vitro assays and applications of high-throughput analysis (e.g. xMAP Multiplexing) to translational clinical research.
To this end, he
is testing the inflammatory mediator content in various milieu such as gingival crevicular fluid, saliva and serum.
has been focused on various the impact of hypoxia on cell functions.
Inflammation-mediated hypoxia is an important mechanism in various pathological processes such as periodontitis (and at large in inflammatory diseases).
Mechanism of gingival fibrosis
has been working on the clinical characterization and the mechanism of fibrotic changes in gingival tissues as a side effect of various medications.
This is an important phenomenon caused by cyclosporin-A (an immunosuppressant widely used in solid organ transplants), phenytoin (an anti-epileptic medication), and various calcium channel blockers used to control hypertension.
Common to all these medications, significant and debilitating fibrotic enlargements of the gingival tissues pose a major problem to patients and affect the quality of life.
In collaboration with Dr. Philip Trackman, Dr. Kantarci
has identified multiple mechanisms for the fibrotic enlargements of the gingival tissues.
has been leading a series of studies on the osteoblast and osteoclast activity in alveolar bone in response to orthodontic tooth movement with or without various methods to enhance the speed of the movement and the bone turnover.
This line of research focuses on techniques to improve the outcomes for orthodontic patients and speed recovery time.
Recent work from Dr. Kantarci's
laboratory has shown that tooth movement was significantly accelerated-a 3 to 4-fold increase-over traditional orthodontic treatment.
A, Augustijn P, Firatli E, Sheff MC, Hasturk H,Graves DT, Trackman PC.
2007. Apoptosis in gingival overgrowth tissues.